This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma Crescita futura

Future criteri di controllo 2/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di 9 Meters Biopharma.

Informazioni chiave

41.4%

Tasso di crescita degli utili

39.9%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	21.6%
Tasso di crescita dei ricavi	56.6%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	30 May 2023

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:2Q3A - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	N/A	-43	N/A	N/A	2
12/31/2024	N/A	-41	N/A	N/A	3
12/31/2023	3	-43	N/A	N/A	4
3/31/2023	N/A	-46	-37	-37	N/A
12/31/2022	N/A	-44	-37	-37	N/A
9/30/2022	N/A	-41	-35	-35	N/A
6/30/2022	N/A	-46	-36	-34	N/A
3/31/2022	N/A	-43	-36	-33	N/A
12/31/2021	N/A	-37	-32	-29	N/A
9/30/2021	N/A	-32	-30	-28	N/A
6/30/2021	N/A	-27	-24	-24	N/A
3/31/2021	N/A	-63	-26	-23	N/A
12/31/2020	N/A	-61	-23	-19	N/A
9/30/2020	N/A	-65	-19	-16	N/A
6/30/2020	N/A	-66	-19	-16	N/A
3/31/2020	N/A	-26	-16	-16	N/A
12/31/2019	N/A	-27	-18	-18	N/A
9/30/2019	N/A	-22	-17	-17	N/A
6/30/2019	N/A	-14	-17	-17	N/A
3/31/2019	N/A	-14	-12	-12	N/A
12/31/2018	N/A	-24	-15	-15	N/A
9/30/2018	N/A	-22	-15	-15	N/A
6/30/2018	N/A	-24	-12	-12	N/A
3/31/2018	N/A	-23	-11	-11	N/A
12/31/2017	N/A	-12	-5	-5	N/A
9/30/2017	N/A	-11	-4	-4	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che 2Q3A rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che 2Q3A rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che 2Q3A rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 2Q3A ( 56.6% all'anno) crescerà più rapidamente del mercato German ( 5.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 2Q3A ( 56.6% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 2Q3A è previsto essere elevato tra 3 anni

This company listing is no longer active

9 Meters Biopharma Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Forecast to breakeven in 2024

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Independent Chairman recently bought €84k worth of stock

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

New 90-day high: €1.86

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: €1.22

New 90-day high: €1.19

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

New 90-day high: €0.85

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

Independent Chairman recently bought €81k worth of stock

New 90-day high - €0.74

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita